NuPathe (PATH) to Cut Workforce 50%, Delay IND for NP202, Cut NP101 Spending

October 9, 2012 7:38 AM EDT Send to a Friend
Get Alerts PATH Hot Sheet
Trade PATH Now!
Join SI Premium – FREE
As previously reported, on September 25, 2012, NuPathe Inc. (Nasdaq: PATH) entered into a Securities Purchase Agreement with certain qualified institutional purchasers and individual investors pursuant to which the Company agreed to sell to the Investors units of the Company’s securities for an aggregate purchase price of $28 million. The closing of the Proposed Financing is subject to certain specified closing conditions. In connection with the Proposed Financing, the Company is undertaking certain cost containment measures in order to focus its expenditures on gaining FDA approval of NP101, securing commercial partners and select pre-launch activities. The cost containment measures include, among others:
  • A 50% reduction in workforce;

  • Reducing expenditures relating to commercialization activities for NP101 and the earlier stage product candidates;

  • Delaying the filing of an Investigational New Drug application for NP202, the Company’s product candidate for the long-term treatment of schizophrenia and bipolar disorder, until a co-development partner is obtained; and

  • The previously reported restructuring of the Company’s outstanding debt under its term loan facility.
The Company believes that the proceeds to be received upon the closing of the Proposed Financing, together with the foregoing cost containment measures, will provide sufficient capital to fund operations into the fourth quarter of 2013.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings, Guidance

Add Your Comment